Attenuation of psoriasis-like skin lesion in a mouse model by topical treatment with indirubin and its derivative E804

Journal of Dermatological Science

Volumn 65, Issue 1, 2012, Pages 70-72

  Miyoshi, Ken ^a   Takaishi, Mikiro ^a   DiGiovanni, John ^b   Sano, Shigetoshi ^a  

^a KOCHI UNIVERSITY   (Japan)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

E804; Indigo naturalis; Indirubin; Psoriasis

Indexed keywords

ANTIPSORIASIS AGENT; E 804; HERBACEOUS AGENT; INDIGO; INDIRUBIN; INTERLEUKIN 22; INVOLUCRIN; KI 67 ANTIGEN; MESSENGER RNA; PLANT MEDICINAL PRODUCT; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; EPIDERMIS; GENE EXPRESSION REGULATION; HERBAL MEDICINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INDIGO NATURALIS; KERATINOCYTE; LETTER; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PSORIASIS; SKIN DEFECT; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; HUMANS; INDOLES; KERATINOCYTES; MALE; MICE; PROSTATIC NEOPLASMS; PSORIASIS; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; SKIN; UP-REGULATION;

EID: 84855192259     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2011.10.001     Document Type: Letter

References (10)

1. Lin Y.K., Leu Y.L., Yang S.H., Chen H.W., Wang C.T., Pang J.H. Anti-psoriatic effects of indigo naturalis on the proliferation and differentiation of keratinocytes with indirubin as the active component. J Dermatol Sci 2009, 54:168-174.
2. Lin Y.K., Chang C.J., Chang Y.C., Wong W.R., Chang S.C., Pang J.H. Clinical assessment of patients with recalcitrant psoriasis in a randomized, observer-blind, vehicle-controlled trial using indigo naturalis. Arch Dermatol 2008, 144:1457-1464.
3. Nam S., Buettner R., Turkson J., Kim D., Cheng J.Q., Muehlbeyer S., et al. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci USA 2005, 102:5998-6003.
4. Hoessel R., Leclerc S., Endicott J.A., Nobel M.E., Lawrie A., Tunnah P., et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1999, 1:60-67.
5. Marko D., Schatzle S., Friedel A., Genzlinger A., Zankl H., Meijer L., et al. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br J Cancer 2001, 84:283-289.
6. Miyoshi K., Takaishi M., Nakajima K., Ikeda M., Kanda T., Tarutani M., et al. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. J Invest Dermatol 2011, 131:108-117.
7. Sano S., Chan K.S., Carbajal S., Clifford J., Peavey M., Kiguchi K., et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005, 11:43-49.
8. Nakajima K., Kanda T., Takaishi M., Shiga T., Miyoshi K., Nakajima H., et al. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J Immunol 2011, 186:4481-4489.
9. Boniface K., Bernard F.X., Garcia M., Gurney A.L., Lecron J.C., Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005, 174:3695-3702.
10. Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 2007, 445:866-873.